| Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab PF Ferrucci, PA Ascierto, J Pigozzo, M Del Vecchio, M Maio, ... Annals of Oncology 27 (4), 732-738, 2016 | 399 | 2016 |
| Uveal melanoma F Spagnolo, G Caltabiano, P Queirolo Cancer treatment reviews 38 (5), 549-553, 2012 | 195 | 2012 |
| BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies F Spagnolo, P Ghiorzo, L Orgiano, L Pastorino, V Picasso, E Tornari, ... OncoTargets and therapy, 157-168, 2015 | 178 | 2015 |
| Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ... Journal for immunotherapy of cancer 8 (2), 2020 | 160 | 2020 |
| Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma F Spagnolo, P Ghiorzo, P Queirolo Oncotarget 5 (21), 10206, 2014 | 157 | 2014 |
| Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases P Queirolo, F Spagnolo, PA Ascierto, E Simeone, P Marchetti, A Scoppola, ... Journal of neuro-oncology 118, 109-116, 2014 | 127 | 2014 |
| Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II … PA Ascierto, M Mandalà, PF Ferrucci, M Guidoboni, P Rutkowski, ... Journal of Clinical Oncology 41 (2), 212-221, 2023 | 104 | 2023 |
| Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: a systematic review P Queirolo, F Spagnolo Cancer Treatment Reviews 59, 71-78, 2017 | 97 | 2017 |
| Current state of target treatment in BRAF mutated melanoma ET Tanda, I Vanni, A Boutros, V Andreotti, W Bruno, P Ghiorzo, ... Frontiers in molecular biosciences 7, 154, 2020 | 93 | 2020 |
| Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy P Queirolo, A Boutros, E Tanda, F Spagnolo, P Quaglino Seminars in cancer biology 59, 290-297, 2019 | 92 | 2019 |
| Current status and perspectives in immunotherapy for metastatic melanoma R Marconcini, F Spagnolo, LS Stucci, S Ribero, E Marra, F De Rosa, ... Oncotarget 9 (15), 12452, 2018 | 89 | 2018 |
| Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: a systematic review F Spagnolo, V Picasso, M Lambertini, V Ottaviano, B Dozin, P Queirolo Cancer treatment reviews 45, 38-45, 2016 | 87 | 2016 |
| Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and … S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ... European Journal of Cancer 142, 18-28, 2021 | 85 | 2021 |
| Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma P Queirolo, V Picasso, F Spagnolo Cancer treatment reviews 41 (6), 519-526, 2015 | 82 | 2015 |
| Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study MP Pistillo, V Fontana, A Morabito, B Dozin, S Laurent, R Carosio, ... Cancer Immunology, Immunotherapy 68, 97-107, 2019 | 77 | 2019 |
| Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind … GV Long, JJ Luke, MA Khattak, L de la Cruz Merino, M Del Vecchio, ... The Lancet Oncology 23 (11), 1378-1388, 2022 | 76 | 2022 |
| Effect of age on melanoma risk, prognosis and treatment response S Ribero, LS Stucci, E Marra, R Marconcini, F Spagnolo, L Orgiano, ... Acta dermato-venereologica 98 (7), 624-629, 2018 | 75 | 2018 |
| Upcoming strategies for the treatment of metastatic melanoma F Spagnolo, P Queirolo Archives of dermatological research 304, 177-184, 2012 | 71 | 2012 |
| Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent N Solari, F Spagnolo, E Ponte, A Quaglia, R Lillini, M Battista, P Queirolo, ... Journal of surgical oncology 109 (3), 270-274, 2014 | 70 | 2014 |
| Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy V Chiarion-Sileni, J Pigozzo, PA Ascierto, E Simeone, M Maio, L Calabrò, ... British journal of cancer 110 (7), 1721-1726, 2014 | 65 | 2014 |
